AI Article Synopsis
- A new type of pyridazine compound that targets p38 MAP kinase shows strong potential as an inhibitor.
- These compounds effectively reduced cytokine release in cell-based tests and performed well in animal models, specifically for rheumatoid arthritis.
- In studies, they significantly lowered TNF-alpha production in mice and showed good results in a rat model of collagen-induced arthritis.
Article Abstract
Novel potent trisubstituted pyridazine inhibitors of p38 MAP (mitogen activated protein) kinase are described that have activity in both cell-based assays of cytokine release and animal models of rheumatoid arthritis. They demonstrated potent inhibition of LPS-induced TNF-alpha production in mice and exhibited good efficacy in the rat collagen induced arthritis model.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2005.02.010 | DOI Listing |
Publication Analysis
Top Keywords
pyridazine inhibitors
8
inhibitors p38
8
p38 map
8
design synthesis
4
synthesis potent
4
potent pyridazine
4
map kinase
4
kinase novel
4
novel potent
4
potent trisubstituted
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!